Lea James is an associate working in the litigation department of Foley & Lardner LLP. Lea is based in the firm’s Boston office where she is a member of the Business Litigation & Dispute Resolution Practice.
Lea served as a summer associate in the firm’s Milwaukee office in both 2017 and 2018.
Prior to joining Foley, Lea served as a research assistant to Professor Owen Jones at Vanderbilt University Law School and assisted in drafting the new edition of the textbook Law and Neuroscience. Before pursuing her legal career, Lea worked for a contract research organization doing preclinical and clinical research involving pharmaceuticals and medical devices, a role in which she worked with both pharmaceutical companies and the FDA.
Presentations and Publications
- Co-author, “Cancer Drugs: Antibody-Drug Conjugate Litigation,” Foley Insights (August 13, 2024)
- Co-author, “Members of Congress Call for DOJ to Investigate Possible Antitrust Violations in Oil Industry,” Foley Insights (June 18, 2024)
- Author, “Pharming Out Data: A Proposal for Promoting Innovation and Public Health through a Hybrid Clinical Data Protection Scheme,” Vanderbilt Journal of Transnational Law (November 2018)
- Co-author, “When a Promise Isn’t Enough—Crafting Proper Employee Patent Assignments,” JD Supra (December 2018)
DOJ Criminal Division Updates (Part 2): Department of Justice Updates its Corporate Criminal Whistleblower Awards Pilot Program
On August 1, 2024, the Department of Justice’s Criminal Division launched a three-year Corporate Whistleblower Awards Pilot Program. In this article, we provide an overview of the Pilot Program and lay out the recent changes to the guidance.
Foley Attorneys Publish on Antitrust Enforcement in Government Procurement
Foley & Lardner LLP attorneys Mark Grundvig, Michelle Freeman, Lea Gulotta James, and Katharine Young authored the Criminal Justice Magazine article, "Antitrust Enforcement in Government Procurement: A Look at Enforcement Trends at the Five-Year Anniversary of the Antitrust Division’s Procurement Collusion Strike Force."
Antibody Drug Conjugates Keep Growing: What You Need to Know
Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.
Antibody Drug Conjugates Keep Growing: What You Need to Know
Since 2018, licensing deals totaling over $60 billion have been signed regarding Antibody Drug Conjugates (ADCs), with 2023 alone having at least 18 deals.
Understanding the Risk vs. Reward of Department of Justice’s Corporate Criminal Whistleblower Awards Pilot
The Securities & Exchange Commission, the Department of Health & Human Services, and other agencies have long had established bounty programs that reward successful tipsters.
Cancer Drugs: Antibody-Drug Conjugate Litigation
The first step to making a product available to the clinical population is often obtaining patent protection, resulting in litigation around ADCs.